In a mid-stage clinical trial, Roche Holding AG's experimental obesity drug enicepatide successfully met its primary objectives, significantly reducing both blood sugar and body weight in overweight or obese patients with type-2 diabetes. Over a 48-week period, patients on the highest 24-milligram dose achieved an average weight loss of 15.5% with no observed plateau, alongside a 2.65% reduction in HbA1c levels. These results bolster Roche's plans to expand its metabolic disease portfolio.
Enicepatide mid-stage trial results
- ▪A mid-stage clinical trial of Roche Holding AG's enicepatide evaluated overweight or obese patients who also had type-2 diabetes
- ▪Results from a mid-stage clinical trial of enicepatide reinforce Roche Holding AG's ambitions to rapidly develop its portfolio of medicines for obesity, diabetes, and cardiovascular disease
- ▪Roche Holding AG's experimental obesity drug enicepatide met the primary objectives of a mid-stage clinical trial by reducing blood glucose and body weight in patients
Blood sugar reduction outcomes
- ▪Patients receiving the highest 24-milligram dose of Roche Holding AG's enicepatide experienced a 2.65% reduction in HbA1c, a measure of blood sugar, after 48 weeks
- ▪In a mid-stage clinical trial of Roche Holding AG's enicepatide, a meaningful proportion of patients treated with the drug achieved normalized glucose levels within less than a year of treatment
Body weight loss outcomes
- ▪The body weight loss in patients treated with the highest 24-milligram dose of Roche Holding AG's enicepatide showed no plateau after 48 weeks
- ▪Patients receiving the highest 24-milligram dose of Roche Holding AG's enicepatide lost an average of 15.5% of their body weight after 48 weeks of treatment
Story comments
Loading comments…